Cure8 research brief
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a clinical study related to Crohn's disease, Infliximab, Anti-TNF, and Tests and monitoring. Use the original source link for the full details.
The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.
Review the original publication for the complete reporting, methods, and context.
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.
A blood biomarker that helps predict primary non-response to anti‑TNF drugs could spare some patients ineffective therapy, reduce delays to alternative treatments, and inform shared decision‑making before starting...
Identifies candidate drug‑level and immune biomarker cut‑points linked with endoscopic healing in pediatric Crohn's disease, which could help guide dosing or treatment changes if validated.
